Analyst consensus rating
Cardiol Therapeutics Analyst Rating: Strong Buy
CRDL is rated Strong Buy by 4 analysts with a $7.95 target. As of 2026-08-23.
Direct answer
Cardiol Therapeutics's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.95.
Forecast evidence checked August 23, 2026.
Get free Cardiol Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.86
- Average price target
- $7.95
- High price target
- $10.08
- Low price target
- $4.98
- Low target gap
- +168%
- Target upside
- +327.5%
- High target gap
- +442%
- Target range width
- 274.1%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cardiol Therapeutics?
Cardiol Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $7.95.
How far are Cardiol Therapeutics's low and high targets from the recorded price?
The low target implies +168%, while the high target implies +442%.
How many analysts are included in Cardiol Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Cardiol Therapeutics's target upside or downside calculated?
The average target of $7.95 is divided by the recorded price of $1.86, then one is subtracted to produce +327.5%. This does not guarantee a future return.
When was Cardiol Therapeutics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.